PANTHERx Specialty Pharmacy® Selected by Paratek to Distribute Nuzyra™ as part of a Limited Pharmacy Network

PANTHERx Specialty Pharmacy, the industry leading independent national specialty pharmacy, has been selected by Paratek Pharmaceuticals, Inc. as a limited pharmacy network provider of its new once-daily oral antibiotic, Nuzyra™ (omadacycline). Nuzyra™ is a tetracycline class antibacterial approved to treat adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

PANTHERx understands the unique and urgent nature of anti-infective therapy management and has created a clinical protocol to meet the needs of all Nuzyra™ patients. Every Nuzyra™ patient at PANTHERx is guided through their journey by knowledgeable members of our staff who understand their conditions and the critical timeline for treatment. PANTHERx provides 24/7 clinical management, patient education, financial assistance support, and therapy adherence monitoring for our Nuzyra™ patients.

Approved in October 2018, Nuzyra™ is manufactured and marketed by Paratek Pharmaceuticals, Inc. Additional information about Nuzyra™ and resources for patient support are available through Nuzyra Central™ and can be found at

About PANTHERx Specialty Pharmacy
PANTHERx Specialty Pharmacy, The Rare Disease Specialty Pharmacy®, is headquartered in Pittsburgh, Pennsylvania. PANTHERx Specialty’s mission is to transform lives by delivering medical breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. Every day we create ways to Reinvent Specialty, Revolutionize Pharmacy, and Redefine Care®, by developing focused solutions, bold innovations, and novel clinical services associated with the life-transforming therapies that we deliver.

PANTHERx was awarded 2018 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy as well as the American Pharmacy Purchasing Alliance. Zitter Health Insights awarded PANTHERx the Specialty Pharmacy Patient Choice Award winner for both 2017 and 2018. As a quad-accredited pharmacy, PANTHERx holds accreditations from VIPPS, ACHC, URAC, and CPPA.

PANTHERx® at Asembia: Paying it Forward

Last week PANTHERx participated in the 2019 Asembia Specialty Pharmacy Summit in Las Vegas, NV, where we met with partners, announced strategic collaborations, unveiled the new PANTHERx brand, and shared insights about the state-of-the-art rare and orphan drugs in the specialty pharmacy industry. We are delighted to have been a part of Asembia for yet another year, especially as this one was particularly exciting for PANTHERx. As always, our patients were on our minds as we attended this summit, and we wanted our partners and peers to be thinking about them as well.


DELIVERxING Hope to Patients with Rare Diseases
During Asembia , PANTHERx Chairman & CEO, Dr. Gordon J. Vanscoy delivered a talk titled DELIVERxING Hope to Patients with Rare Diseases: Improving Orphan/Precision Medicine Channels. His talk was well attended, and Dr. Vanscoy was able to share PANTHERx’s patient-focused mission and explain how PANTHERx is ideally positioned to manage complex treatments and unique patient journeys.
A review of Vanscoy’s speaker session can be read on the Specialty Pharmacy Continuum website:

Supporting Organizations that Support Our Patients
PANTHERx not only wanted to discuss the importance of putting patients first, we wanted to involve our partners and colleagues in a way that would impact our patients directly. During our “Sweets in the PANTHERx Suite” event on Sunday evening prior to Asembia, PANTHERx gave each of our event attendees the opportunity to help PANTHERx support organizations that support our patients. Attendees could choose to allocate a specified dollar value to either Global Genes, the Susan G. Komen Foundation, or the American Cancer Society, that PANTHERx would donate on their behalf. The result was thousands of dollars in donations from PANTHERx to these deserving support organizations.


We thank Asembia for this meeting platform and for providing us an opportunity to further our mission, create awareness for disease states that we support, and provide hope and support to our patients.